https://doi.org/10.55788/f0ce375e
Prof. Diamant Thaçi (University of Lübeck, Germany) presented results on the assessment of the IL-17 A/F inhibitor bimekizumab as a treatment for patients suffering from both PsA and active psoriasis up to 1 year [1]. The new analysis used data from the phase 3 trials BE OPTIMAL (NCT03895203) with patients naïve to biologic DMARDs and BE COMPLETE (NCT03896581) assessing patients with an inadequate prior response to TNF inhibitors.
BE OPTIMAL (BO) included 852 participants who received either placebo, adalimumab as a reference, or bimekizumab at a dose of 160 mg every 4 weeks. BE COMPLETE (BC) enrolled 400 participants who were randomised to placebo or bimekizumab at the same regimen. Both trials comprised a double-blind period to week 16 with a primary endpoint of ACR50 and an open-label extension up to week 52. Their inclusion criteria required a skin involvement of at least 3% of body surface area (BSA) at baseline.
At week 16, bimekizumab was superior to placebo in joint, radiographic, and skin outcomes in both trials [2,3]. At week 52, the overall results in BO showed ACR50 responses over 60% irrespective of starting on placebo up to week 16 [1]. In BC, the ACR50 response rates in the non-responder imputation (NRI) population were 47.7%/56.3% depending on being on the study drug since week 16 or from the start.
Prof. Thaçi pointed out that the analysis particularly looked at the subgroups with moderate (≥3 to ≤10%) and severe (≥10%) BSA involvement, as these patients are of special interest to dermatologists. ACR50 was achieved in 60.9%/56.3% (BO) and 41.3%/55.0% (BC) of patients with moderate BSA involvement. The corresponding values for BSA ≥10% were 64.6%/69.9% (BO) and 64.0%/58.2% (BC), respectively.
The target of ≤1 SJC was reached in BO and BC by overall 70–80%. In both trials, PASI scores of 1 or less were observed in 73–82% in the subgroups with a BSA ≥3 to ≤10% and 65.7–81.3% with a BSA of at least 10. The analysis also looked at the very high bar of ACR50 plus PASI100 response at week 52. “Roughly 50% of bDMARD-naïve patients in BO achieved that, while the TNF-experienced are also showing a very good response,” Prof. Thaçi revealed. For the subgroups with moderate and severe BSA involvement this combined response was achieved, for example in BO, in over 40% and over 50%.
For both trials, the safety profile was consistent with known results. Prof. Thaçi additionally indicated that all cases of candidiasis were mild or moderate.
- Thaçi D. Bimekizumab efficacy and safety in patients with active psoriatic arthritis and psoriasis: 52-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies. 4, EADV Congress 2023, 11–14 October, Berlin, Germany.
- McInnes IB, et al. Lancet. 2023;401:25–37.
- Merola JF, et al. Lancet. 2023;401:38–48.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« High-dose subcutaneous spesolimab prevents GPP flares up to week 48 Next Article
Severe hand eczema: dupilumab could be a future treatment »
« High-dose subcutaneous spesolimab prevents GPP flares up to week 48 Next Article
Severe hand eczema: dupilumab could be a future treatment »
Table of Contents: EADV 2023
Featured articles
Tapinarof on course to become a new topical treatment in AD
AD and Eczema in 2023
Tapinarof on course to become a new topical treatment in AD
Upadacitinib provides sustained skin clearance in adolescents and adults with AD
Sustained deep clinical and itch responses with novel IL-13 inhibitor
IL-13 inhibitor shows potential in atopic dermatitis
Encouraging results for amlitelimab in atopic dermatitis
Chronic hand eczema: patients share similar molecular signatures regardless of AD status
Severe hand eczema: dupilumab could be a future treatment
Psoriasis News
Dual IL-17 blockade yields efficacy on joints and skin
High-dose subcutaneous spesolimab prevents GPP flares up to week 48
Drug survival of guselkumab and risankizumab seems superior to other biologics
IL-23 blockers may lower the risk of developing inflammatory and psoriatic arthritis
First-in-class oral IL-23 inhibitor safe and effective for moderate-to-severe plaque psoriasis
Hidradenitis Suppurativa: End of the Diagnostic and Therapeutic Draught
Skin tape stripping allows a novel precision medicine approach in HS
Nanobodies: A novel way to treat HS
Anti-IL17 blockade leads to maintained pain reduction in patients with HS
Vitiligo: Novel Treatment Options
JAK1 inhibition: a promising forthcoming treatment option in vitiligo
Vitiligo: Continuation of topical ruxolitinib successful in many initial non-responders
Alopecia Areata: Novel Developments
JAK3/TEC inhibition achieves clinically meaningful responses in AA
Alopecia areata: remarkable regrowth rates with deuruxolitinib
Botanical drug solution improves hair regrowth in children and adolescents with AA
What’s New in Other Disease Entities
Nemolizumab shows high success rates in prurigo nodularis
Remibrutinib reduces itch, sleep problems, and activity impairment in patients with CSU
Innovative wound gel reduces frequency of painful dressing changes in epidermolysis bullosa
Best of the Posters
Women with psoriasis face increased adverse effects with systemic therapy
Improved AI tool shows high sensitivity rates in skin cancer detection
Dermoscopy training combined with AI significantly improves skin cancer detection
Related Articles

May 10, 2023
Melanoma: Surveillance and follow-up
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com